Want to see BYSI full AI Analyst Report?
Beyondspring (BYSI) AI Stock Analysis
Beyondspring
(NASDAQ:BYSI)
BYSI scores near the low end of the range, driven primarily by a severely strained financial position: zero revenue, negative stockholders' equity of -$32M, a shrinking $26M asset base, and roughly $20M of annual cash burn that raises going-concern and financing questions. Technicals reinforce the caution, with the stock trading well below all key moving averages and negative MACD momentum. Valuation provides no anchor given negative earnings and no dividend. Partially offsetting these risks are a dramatic reduction in losses and cash burn, a capital-efficient China partnership for the Phase 3 DUBLIN-4 trial, FDA Fast Track designation, and an ATM facility for added funding flexibility — but dual Nasdaq listing-compliance deficiencies make this a highly speculative, binary situation dependent on pipeline outcomes.
Beyondspring (BYSI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $26.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 859.40K
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- -0.29
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 44
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Beyondspring Business Overview & Revenue Model
Company Description
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced throu...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Beyondspring has historically not relied on recurring product sales as its primary source of revenue because its key product candidates (including plinabulin) have been in development and subject to clin...
Beyondspring Financial Statement Overview
Summary
The financial profile is extremely weak. BeyondSpring generates no revenue, has posted continuous net losses, and carries deeply negative stockholders' equity of -$32.2M with total assets shrinking from $117M (2020) to $25.9M (2025). Operating cash outflows of roughly $20M per year against this shrinking asset base raise clear going-concern risk. The only positives are sharply reduced losses (from -$64M in 2021 to -$8.5M in 2025), narrowed cash burn, and minimal debt of $320K — meaningful cost discipline, but not enough to offset the absence of any revenue base.
Income Statement
12Very NegativeBalance Sheet
8Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 1.35M | 1.35M |
| Gross Profit | -38.00K | -87.00K | 0 | -302.00K | 1.35M | 1.35M |
| EBITDA | -7.87M | -8.54M | -8.48M | -13.62M | -35.87M | -64.49M |
| Net Income | -6.68M | -7.99M | -11.12M | -21.03M | -33.28M | -64.18M |
Balance Sheet | ||||||
| Total Assets | 14.61M | 25.93M | 34.31M | 24.81M | 46.22M | 81.65M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 12.56M | 2.92M | 15.34M | 37.27M | 72.37M |
| Total Debt | 171.00K | 320.00K | 589.00K | 847.00K | 4.96M | 3.58M |
| Total Liabilities | 50.63M | 49.92M | 48.60M | 48.27M | 49.23M | 60.73M |
| Stockholders Equity | -35.57M | -32.16M | -32.90M | -26.80M | -5.98M | 26.68M |
Cash Flow | ||||||
| Free Cash Flow | -17.05M | -20.07M | -16.67M | -16.57M | -28.18M | -50.09M |
| Operating Cash Flow | -17.05M | -20.02M | -16.44M | -16.47M | -28.15M | -47.24M |
| Investing Cash Flow | 1.26M | 13.48M | -12.01M | -100.00K | 18.25M | -20.41M |
| Financing Cash Flow | -2.24M | 2.27M | 26.79M | 4,000 | 3.43M | 1,000 |
Beyondspring Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BYSI, the sentiment is Neutral. The current price of 0.64 is above the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.66, and below the 200-day MA of 1.27, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 54.08 is Neutral, neither overbought nor oversold. The STOCH value of 66.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BYSI.
Beyondspring Risk Analysis
Beyondspring disclosed 87 risk factors in its most recent earnings report. Beyondspring reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskBeyondspring Peers Comparison
Overall Rating
XFOR55Neutral
PRLD53Neutral
GANX48Neutral
ABVC43Neutral- BYSI41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| XFOR | 55Neutral | $332.14M | -2.79 | -63.05% | ― | -51.65% | 91.93% |
| PRLD | 53Neutral | $309.64M | -4.91 | -75.35% | ― | 220.34% | 55.73% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GANX | 48Neutral | $49.32M | -2.26 | -161.58% | ― | ― | 23.02% |
| ABVC | 43Neutral | $26.69M | -3.39 | -71.47% | ― | -100.00% | -55.90% |
| BYSI | 41Neutral | $26.47M | -3.90 | 19.96% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BYSI | Beyondspring | 0.64 | -1.43 | -68.94% | |
| XFOR | X4 Pharmaceuticals | 3.35 | -0.74 | -18.09% | |
| ABVC | ABVC BioPharma, Inc. | 1.00 | -1.96 | -66.22% | |
| PRLD | Prelude Therapeutics, Inc. | 3.88 | -0.10 | -2.51% | |
| GANX | Gain Therapeutics, Inc. | 1.13 | -0.71 | -38.59% |
Beyondspring Corporate Events
BeyondSpring Shareholders Ratify 2026 Auditor Appointment
PositiveBeyondSpring Inc. held its 2026 annual meeting of shareholders on October 13, 2026, with 20,905,921 ordinary shares present or represented by proxy, amounting to approximately 50.84% of the 41,119,820 shares outstanding and entitled to vote as of the...
BeyondSpring Divests China Assets, Refocuses on Data Partnerships
NeutralOn September 30, 2026, BeyondSpring completed the sale of all its ownership interests in BeyondSpring Ltd., which indirectly held its majority stake in China-based Dalian Wanchunbulin Pharmaceuticals, to Hong Kong’s Biolin Investment. The trans...
BeyondSpring Faces Nasdaq Listing Compliance Risk
NegativeOn September 29, 2026, BeyondSpring Inc. disclosed that Nasdaq notified the company its market value of listed securities had fallen below the $35 million minimum for 30 straight business days, breaching the Capital Market’s continued listing s...
BeyondSpring launches ATM program to bolster financing
PositiveOn September 28 and 29, 2026, BeyondSpring entered into a share purchase and strategic collaboration with Biolin Investment and its Chinese subsidiary Bulin, and launched an at-the-market equity program. Under the collaboration, BeyondSpring will sel...
BeyondSpring Faces Nasdaq Noncompliance Over Minimum Bid Price
NegativeOn September 17, 2026, BeyondSpring Inc. received notice from Nasdaq that its ordinary shares had traded below the $1.00 minimum bid price for 30 consecutive business days, placing the company out of compliance with Nasdaq’s continued listing r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026